类风湿性关节炎患者在治疗前和治疗中需要考虑什么?]

Q4 Medicine
Praxis Pub Date : 2025-03-01 DOI:10.23785/PRAXIS.2025.03.006
Melanie Kraus, Kriemhild Lippay
{"title":"类风湿性关节炎患者在治疗前和治疗中需要考虑什么?]","authors":"Melanie Kraus, Kriemhild Lippay","doi":"10.23785/PRAXIS.2025.03.006","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Rheumatoid arthritis (RA) is the most common chronic inflammatory autoimmune disease in Switzerland, affecting up to 1 % of patients. Accordingly, these patients are also frequently seen in general practitioner consultations. The first-line therapy consists of methotrexate +/- glucocorticoids. Further disease modifying antirheumatic drugs (DMARDs) are necessary depending on symptom control, disease activity and side effects. Therapy goals are 1. improving quality of life, 2. preventing bone destruction and 3. controlling inflammation and thus reducing cardiovascular mortality. Patients with RA have an increased risk of infection due to their disease and therapy. Vaccination status should be checked and screening for relevant infectious diseases should be carried out before starting treatment. This article is intended to provide an overview of the treatment options as well as screening and prophylaxis of infections in accordance with the current recommendations of the European Alliance of Associations for Rheumatology (EULAR) and the Swiss Society of Rheumatology (SGR).</p>","PeriodicalId":20494,"journal":{"name":"Praxis","volume":"114 3","pages":"105-110"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[The patient with rheumatoid arthritis in general practice - what needs to be considered before and during therapy?]\",\"authors\":\"Melanie Kraus, Kriemhild Lippay\",\"doi\":\"10.23785/PRAXIS.2025.03.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Rheumatoid arthritis (RA) is the most common chronic inflammatory autoimmune disease in Switzerland, affecting up to 1 % of patients. Accordingly, these patients are also frequently seen in general practitioner consultations. The first-line therapy consists of methotrexate +/- glucocorticoids. Further disease modifying antirheumatic drugs (DMARDs) are necessary depending on symptom control, disease activity and side effects. Therapy goals are 1. improving quality of life, 2. preventing bone destruction and 3. controlling inflammation and thus reducing cardiovascular mortality. Patients with RA have an increased risk of infection due to their disease and therapy. Vaccination status should be checked and screening for relevant infectious diseases should be carried out before starting treatment. This article is intended to provide an overview of the treatment options as well as screening and prophylaxis of infections in accordance with the current recommendations of the European Alliance of Associations for Rheumatology (EULAR) and the Swiss Society of Rheumatology (SGR).</p>\",\"PeriodicalId\":20494,\"journal\":{\"name\":\"Praxis\",\"volume\":\"114 3\",\"pages\":\"105-110\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Praxis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23785/PRAXIS.2025.03.006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Praxis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23785/PRAXIS.2025.03.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

简介:类风湿性关节炎(RA)是瑞士最常见的慢性炎症性自身免疫性疾病,影响高达1%的患者。因此,这些患者也经常出现在全科医生咨询。一线治疗包括甲氨蝶呤+/-糖皮质激素。根据症状控制、疾病活动性和副作用,进一步使用疾病改善抗风湿药物(DMARDs)是必要的。治疗目标:1。2.提高生活质量;2 .防止骨质破坏;控制炎症,从而降低心血管疾病死亡率。类风湿性关节炎患者由于其疾病和治疗,感染的风险增加。应检查疫苗接种情况,并在开始治疗前进行相关传染病筛查。本文旨在根据欧洲风湿病协会联盟(EULAR)和瑞士风湿病学会(SGR)目前的建议,概述治疗方案以及筛查和预防感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[The patient with rheumatoid arthritis in general practice - what needs to be considered before and during therapy?]

Introduction: Rheumatoid arthritis (RA) is the most common chronic inflammatory autoimmune disease in Switzerland, affecting up to 1 % of patients. Accordingly, these patients are also frequently seen in general practitioner consultations. The first-line therapy consists of methotrexate +/- glucocorticoids. Further disease modifying antirheumatic drugs (DMARDs) are necessary depending on symptom control, disease activity and side effects. Therapy goals are 1. improving quality of life, 2. preventing bone destruction and 3. controlling inflammation and thus reducing cardiovascular mortality. Patients with RA have an increased risk of infection due to their disease and therapy. Vaccination status should be checked and screening for relevant infectious diseases should be carried out before starting treatment. This article is intended to provide an overview of the treatment options as well as screening and prophylaxis of infections in accordance with the current recommendations of the European Alliance of Associations for Rheumatology (EULAR) and the Swiss Society of Rheumatology (SGR).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Praxis
Praxis Medicine-Medicine (all)
CiteScore
0.40
自引率
0.00%
发文量
146
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信